田驰,拱梅芳,孙天宇,孙明杰
TIAN Chi,GONG Meifang,SUN Tianyu,SUN Mingjie

• 1:中南大学药学院
• 2:湘北威尔曼制药股份有限公司

摘要(Abstract)：

糖尿病视网膜病变(diabetic retinopathy,DR)是糖尿病(diabetes mellitus,DM)最严重的并发症之一,具有很高的致盲率。DR发病机制复杂,至今未明。本文对白细胞介素IL-1β(Interleukin-1,IL-1β)在DR、DM中的作用和IL-1β对与DR发病过程中其他炎症因子的影响做一综述。
Diabetic retinopathy is one of the most severe diabetes complications with a high rate of blindness. The mechanism underlying the development of diabetic retinopathy is extremely complicated,and has not been elucidated yet. Here,we reviewed the role of interleukin-1β and the implication of the other inflammation factors during the progress of diabetes mellitus and diabetic retinopathy.

关键词(KeyWords)： 糖尿病;糖尿病视网膜病变;IL-1β;药物研发
diabetes;diabetes retinopathy;interleukin-1β;drug development

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 田驰,拱梅芳,孙天宇,孙明杰
TIAN Chi,GONG Meifang,SUN Tianyu,SUN Mingjie

参考文献(References)：

• [1]吴晓惠,唐流刚,王标,等.滑液尿酸及白细胞介素-1β、白细胞介素-6、肿瘤坏死因子-α与膝骨关节炎相关性研究[J].华西医学,2015,10:1-4.
• [2]郭峰,杨华,屈秋民.白细胞介素1与阿尔茨海默病[J].中国临床康复,2006,18:123-125.
• [3]兰文,陆燕,王春红,等.糖尿病视网膜病变炎症的研究新进展[J].眼科新进展,2013,02:197-200.
• [4]李丽,任骞,叶存喜.糖尿病视网膜病变治疗的临床研究新进展[J].河北医科大学学报,2013,12:1606-1609.
• [5]Souter AJ,Garry M G.Spinal interleukin-1βreduces inflammatory pain[J].Pain,2000,86(1):63-68.
• [6]Safieh-Garabedian B,Kanaan SA,Haddad JJ,et al.Involvement of interleukin‐1β,nerve growth factor and prostaglandin E2 in endotoxin-induced localized inflammatory hyperalgesia[J].British journal of pharmacology,1997,121(8):1619-1626.
• [7]Donath MY,Schumann DM,Faulenbach M,et al.Islet Inflammation in Type 2 Diabetes From metabolic stress to therapy[J].Diabetes care,2008,31(Supplement 2):S161-S164.
• [8]Boni-Schnetzler M,Boller S,Debray S,et al.Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I[J].Endocrinology,2009,150(12):5218-5229.
• [9]刘立峰,刘玉和,沈维高,等.白细胞介素-1的结构,来源,分布,功能及其与疾病的关系[J].北华大学学报:自然科学版,2006,7(5):416-423.
• [10]Leon LR.Invited review:cytokine regulation of fever:studies using gene knockout mice[J].Journal of Applied Physiology,2002,92(6):2648-2655.
• [11]张萃,吴迪,张伟华.鼠重组白细胞介素-1对小鼠下丘脑-垂体-肾上腺轴的影响[J].基础医学与临床,2001,05:465-466.
• [12]Ueda S,Kato S,Matsuoka H,et al.Regulation of cytokineinduced nitric oxide synthesis by asymmetric dimethylarginine:role of dimethylarginine dimethylaminohydrolase[J].Circulation research,2003,92(2):226-233.
• [13]麻玲玲,颜纯.IL-1及NO破坏胰岛β细胞机制的研究进展[J].中国糖尿病杂志,1999,02:38-39.
• [14]Scuderi S,D’amico A G,Federico C,et al.Different Retinal Expression Patterns of IL-1α,IL-1β,and Their Receptors in a Rat Model of Type 1 STZ-Induced Diabetes[J].Journal of Molecular Neuroscience,2015:1-9.
• [15]Takaesu G,Ninomiya-Tsuji J,Kishida S,et al.Interleukin-1(IL-1)receptor-associated kinase leads to activation of TAK1by inducing TAB2 translocation in the IL-1 signaling pathway[J].Molecular and cellular biology,2001,21(7):2475-2484.
• [16]Aguirre V,Werner E D,Giraud J,et al.Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action[J].The Journal of biological chemistry,2002,277(2):1531-1537.
• [17]Emanuelli B,Glondu M,Filloux C,et al.The potential role of SOCS-3 in the interleukin-1β-induced desensitization of insulin signaling in pancreatic beta-cells[J].Diabetes,2004,53(suppl 3):S97-S103.
• [18]Eguez L,Lee A,Chavez JA,et al.Full intracellular retention of GLUT4 requires AS160 Rab GTPase activating protein[J].Cell metabolism,2005,2(4):263-272.
• [19]Sayin N,Kara N,Pekel G.Ocular complications of diabetes mellitus[J].World journal of diabetes,2015,6(1):92.
• [20]Cheema B S,Sharma R,Bhansali A,et al.Endothelial nitric oxide synthase gene polymorphism and type 2 diabetic retinopathy among Asian Indians[J].Acta diabetologica,2012,49(6):481-488.
• [21]Makita S,Nakamura M,Yoshida H,et al.Autocrine growth inhibition of IL-1β-treated cultured human aortic smooth muscle cells:Possible role of nitric oxide[J].Heart and vessels,1996,11(5):223-228.
• [22]Kowluru RA,Koppolu P,Chakrabarti S,et al.Diabetes-induced activation of nuclear transcriptional factor in the retina,and its inhibition by antioxidants[J].Free radical research,2003,37(11):1169-1180.
• [23]刘骁,程娟.2型糖尿病视网膜病变IL-1和TNF-α水平及其临床意义[J].中外医学研究,2015,10:73-74.
• [24]田林红,陈雪红,倪安民,等.糖尿病患者血IL-1,IL-6,IFNγ测定及临床意义[J].实用医学杂志,2000,07:538-539.
• [25]凯思琳,庄稼英.为什么一些1型糖尿病患者可以避免发生并发症[J].糖尿病天地(临床),2011,06:272-273.
• [26]Vallejo S,Palacios E,Romacho T,et al.The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats[J].Cardiovascular diabetology,2014,13(1):158.
• [27]Malozowski S,Sahlroot JT,Larsen CM,et al.Interleukin-1-receptor antagonist in type 2 diabetes mellitus[J].The New England journal of medicine,2007,357(3):302-3;author reply 303.
• [28]Owyang AM,Maedler K,Gross L,et al.XOMA 052,an antiIL-1βmonoclonal antibody,improves glucose control andβ-cell function in the diet-induced obesity mouse model[J].Endocrinology,2010,151(6):2515-2527.
• [29]Meyer K,Der K,Ma J,et al.A 26-Week Repeat-Dose Toxicity Study in Cynomolgus Monkeys With Xoma 052,a Novel Monoclonal Antibody Targeting IL-1 Beta[C]//INTERNATIONAL JOURNAL OF TOXICOLOGY.2455 TELLER RD,THOUSAND OAKS,CA 91320 USA:SAGE PUBLICATIONS INC,2010,29(1):89-89.
• [30]Rissanen A,Howard CP,Botha J,et al.Effect of anti‐IL‐1βantibody(canakinumab)on insulin secretion rates in impaired glucose tolerance or type 2 diabetes:results of a randomized,placebo‐controlled trial[J].Diabetes,Obesity and Metabolism,2012,14(12):1088-1096.
• [31]Pafili K,Papanas N,Maltezos E.Gevokizumab in type 1 diabetes mellitus:extreme remedies for extreme diseases[J]?Expert opinion on investigational drugs,2014,23(9):1277-1284.
• [32]李晓红,李蒙,陶艳蓉.大黄酸及其衍生物药理作用研究新进展[J].现代药物与临床,2010,06:417-421+452.
• [33]Bolton WK,Cattran DC,Williams ME,et al.Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy[J].American journal of nephrology,2004,24(1):32-40.
• [34]Kato N,Yashima S,Suzuki T,et al.Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats[J].Journal of diabetes and its complications,2003,17(6):374-379.
• [35]Aiello LP,Cahill MT,Cavallerano JD.Growth factors and protein kinase C inhibitors as novel therapies for the medical management diabetic retinopathy[J].Eye,2004,18(2):117-125.
• [36]Macugen Diabetic Retinopathy Study Group.Changes in retinal neovascularization after pegaptanib(Macugen)therapy in diabetic individuals[J].Ophthalmology,2006,113(1):23-28.
• [37]Nguyen QD,Tatlipinar S,Shah SM,et al.Vascular endothelial growth factor is a critical stimulus for diabetic macular edema[J].American journal of ophthalmology,2006,142(6):961-969.e4.
• [38]Becerra E,Morescalchi F,Gandolfo F,et al.Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration[J].Current drug targets,2011,12(2):149-172.
• [39]Yilmaz T,Weaver CD,Gallagher MJ,et al.Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema:a systematic review[J].Ophthalmology,2009,116(5):902-913.